Onkologie. 2020:14(2):88-92 | DOI: 10.36290/xon.2020.016

Obstacles of the laboratory screening methods - the "-omic" era?

Monika Náležinská¹, Lenka Zdražilová Dubská², Dalibor Valík², Lenka Hernychová³, Tomáš Pavlík⁴, Monika Mazalová⁴, Josef Chovanec¹, Vuk Fait¹

¹ Oddělení gynekologické onkologie Kliniky operační onkologie MOÚ v Brně

² Oddělení laboratorní medicíny MOÚ, Brno

³ Research Centre for Applied Molecular Oncology MOÚ, Brno

⁴ Institut biostatistiky a analýz, Lékařská fakulta Masarykovy univerzity, Brno

Up to date publications have always considered ovarian carcinoma to be an unpreventable disease. Respectively there has not been yet identified a screening method or a combination of methods for population application. Herewith we are presenting the history of laboratory methods and their present use. This is our introduction of the results of two pilot studies. First, we examined the serum levels of vascular endothelial growth factor VEGF D to be a potential biomarker of early ovarian carcinoma with interesting data. Second pilot study presents the results of measurement of specific glycan profiles in association with resistance to platinum chemotherapy and to the overall survival. Biomarker CA 125 cannot be used as a population screening method, as we have explained. The interpretation of the elevated levels of CA 125 is confusing. For the future biomarker we expect not only high sensitivity and specificity rate. Ideally, we plan this biomarker itself or in combination to predict the specific therapeutic method for the patient with potentially best results for overall survival.

Keywords: gynaecologic onkology, ovarian carcinoma, screening, vascular endothelial growth factor VEGF, glycomics.

Published: June 2, 2020  Show citation